Tzield (Teplizumab)
zm - Zahnärztliche Mitteilungen
Tzield is an immunomodulatory therapy approved by the FDA for delaying the progression from prediabetes (stage 2) to manifest type 1 diabetes (stage 3) in adults and pediatric patients aged 8 years and older. The medication binds to specific immune system cells and delays progression to stage 3 type 1 diabetes by deactivating immune cells that attack insulin-producing cells while increasing the proportion of cells that help mitigate immune response. Tzield is administered as an intravenous infusion once daily over 14 consecutive days.
Produktinformationen
| Hersteller | zm - Zahnärztliche Mitteilungen |
|---|
Mehr Produkte
Ihnen fehlen Informationen oder Dateien?
